Parkinson's disease-the debate on the clinical phenomenology, aetiology, pathology and pathogenesis

Journal of Parkinson's Disease

Volumn 3, Issue 1, 2013, Pages 1-11

  Jenner, Peter ^a   Morris, Huw R ^b   Robbins, Trevor W ^c   Goedert, Michel ^d   Hardy, John ^e   Ben Shlomo, Yoav ^f   Bolam, Paul ^g   Burn, David ^h   Hindle, John V ⁱ   Brooks, David ^j  

^a Guy's Campus   (United Kingdom)

^b CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d MRC LABORATORY OF MOLECULAR BIOLOGY   (United Kingdom)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

^f UNIVERSITY OF BRISTOL   (United Kingdom)

^g MRC Anat Neuropharmacology Unit   (United Kingdom)

^h NEWCASTLE UNIVERSITY   (United Kingdom)

ⁱ BANGOR UNIVERSITY   (United Kingdom)

^j HAMMERSMITH HOSPITAL   (United Kingdom)

more..

Author keywords

aetiology; Parkinson's disease; pathogenesis; pathology; phenomenology; synucleinopathies

Indexed keywords

ALPHA SYNUCLEIN; DJ 1 PROTEIN; GLUCOSYLCERAMIDASE; LEUCINE RICH REPEAT KINASE 2; LEVODOPA; PARKIN; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ALZHEIMER DISEASE; COGNITIVE DEFECT; DEMENTIA; DEPRESSION; DISEASE COURSE; DJ 1 GENE; ENVIRONMENTAL FACTOR; GBA GENE; GENE; GENE MUTATION; GENETIC ASSOCIATION; GENETIC SCREENING; GENETIC VARIABILITY; HEREDITY; HLA GENE; HUMAN; LEWY BODY; LRRK2 GENE; MAPT GENE; MENTAL DISEASE; NEUROLOGIC DISEASE; PARASOMNIA; PARKINSON DISEASE; PATHOGENESIS; PATHOPHYSIOLOGY; PHENOMENOLOGY; PHENOTYPE; PINK1 GENE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SYMPTOMATOLOGY; UNSPECIFIED SIDE EFFECT;

EID: 84880229894     PISSN: 18777171     EISSN: 1877718X     Source Type: Journal    
DOI: 10.3233/JPD-130175     Document Type: Review

References (119)

1. Parkinson J (1817) An essay on the shaking palsy. Sherwood, Neely and Jones, London.
2. Lees AJ, Hardy J, & Revesz T (2009) Parkinson's disease. The Lancet, 373(9680), 2055-2066.
3. Dickson DW (2012) Parkinson's disease and parkinsonism: Neuropathology. Cold Spring Harbor Perspectives in Medicine, 2(8), 9009258.
4. Chaudhuri KR, Healy DG, & Schapira AHV (2006) Nonmotor symptoms of Parkinson's disease: Diagnosis and management. Lancet Neurology, 5(3), 235-245.
5. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, et al. (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science (New York, N.Y.), 276(5321), 2045-2047.
6. Spillantini MG, & Goedert M (2000) The alphasynucleinopathies: Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy. Annals of the New York Academy of Sciences, 920, 16-27.
7. Dubois B, Feldman HH, Jacova C, Cummings JL, Dekosky ST, Barberger-Gateau P, et al. (2010) Revising the definition of Alzheimer's disease: A new lexicon. Lancet Neurology, 9(11), 1118-1127.
8. Gibb WR, & Lees AJ (1988) The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. Journal of Neurology, Neurosurgery & Psychiatry, 51(6), 745-752.
9. Hughes AJ, Daniel SE, Ben-Shlomo Y, & Lees AJ (2002) The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain: A Journal of Neurology, 125(Pt 4), 861-870.
10. Siderowf A, & Stern MB (2008) Premotor Parkinson's disease: Clinical features, detection, and prospects for treatment. Annals of Neurology, 64(Suppl 2), S139-47.
11. Selikhova M, Williams DR, Kempster PA, Holton JL, Revesz T, & Lees AJ (2009) A clinico-pathological study of subtypes in Parkinson's disease. Brain: A Journal of Neurology, 132(Pt 11), 2947-57.
12. Allcock LM, Kenny RA, Mosimann UP, Tordoff S,Wesnes KA, Hildreth AJ, et al. (2006) Orthostatic hypotension in Parkinson's disease: Association with cognitive decline International Journal of Geriatric Psychiatry, 21(8), 778-783.
13. Williams-Gray CH, Foltynie T, Brayne CEG, Robbins TW, & Barker RA (2007) Evolution of cognitive dysfunction in an incident Parkinson's disease cohort. Brain: A Journal of Neurology, 130(Pt 7), 1787-1798.
14. Winder-Rhodes SE, Evans JR, Ban M, Mason SL,Williams-Gray CH, Foltynie T, et al. (2013) Glucocerebrosidase mutations influence the natural history of Parkinson's disease in a community-based incident cohort. Brain:AJournal of Neurology, 136(Pt 2), 392-399.
15. Quinn N, Critchley P, & Marsden CD (1987) Young onset Parkinson's disease. Movement Disorders: Official Journal of the Movement Disorder Society, 2(2), 73-91.
16. Schrag A, & Schott JM (2006) Epidemiological, clinical, and genetic characteristics of early-onset parkinsonism. Lancet Neurology, 5(4), 355-363.
17. Wickremaratchi MM, Ben-Shlomo Y, & Morris HR (2009) The effect of onset age on the clinical features of Parkinson's disease. European Journal of Neurology: The Official Journal of the European Federation of Neurological Societies, 16(4), 450-456.
18. Wickremaratchi MM, Knipe MDW, Sastry BSD, Morgan E, Jones A, Salmon R, et al. (2011) The motor phenotype of Parkinson's disease in relation to age at Onset. Movement Disorders: Official Journal of the Movement Disorder Society, 26(3), 457-463.
19. Dickson DW, Braak H, Duda JE, Duyckaerts C, Gasser T, Halliday GM, et al. (2009) Neuropathological assessment of Parkinson's disease: Refining the diagnostic criteria. Lancet Neurology, 8(12), 1150-1157.
20. Braak H, Del Tredici K, R̈ub U, De Vos RAI, Jansen Steur ENH, & Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiology of Aging, 24(2), 197-211.
21. Papp MI, Kahn JE, & Lantos PL (1989) Glial cytoplasmic inclusions in the CNS of patients with multiple system atrophy (striatonigral degeneration, olivopontocerebellar atrophy and Shy-Drager syndrome). Journal of the Neurological Sciences, 94(1-3), 79-100.
22. Wakabayashi K, Yoshimoto M, Tsuji S, & Takahashi H (1998) Alpha-synuclein immunoreactivity in glial cytoplasmic inclusions in multiple system atrophy. Neuroscience Letters, 249(2-3), 180-182.
23. Spillantini MG, Crowther RA, Jakes R, Cairns NJ, Lantos PL, & Goedert M (1998) Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies. Neuroscience Letters, 251(3), 205-208.
24. Tu PH, Galvin JE, Baba M, Giasson B, Tomita T, Leight S, et al. (1998) Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble alpha-synuclein. Annals of Neurology, 44(3), 415-422.
25. Ahmed Z, Asi YT, Sailer A, Lees AJ, Houlden H, Revesz T, et al. (2012) The neuropathology, pathophysiology and genetics of multiple system atrophy. Neuropathology and Applied Neurobiology, 38(1), 4-24.
26. Goedert M, Clavaguera F, & Tolnay M (2010) The propagation of prion-like protein inclusions in neurodegenerative diseases. Trends in Neurosciences, 33(7), 317-325.
27. Gwinn-Hardy K, Mehta ND, Farrer M, Maraganore D, Muenter M, Yen SH, et al. (2000) Distinctive neuropathology revealed by alpha-synuclein antibodies in hereditary parkinsonism and dementia linked to chromosome 4p. Acta Neuropathologica, 99(6), 663-672.
28. Obi T, Nishioka K, RossOA, Terada T,Yamazaki K, Sugiura A, et al. (2008) Clinicopathologic study of a SNCA gene duplication patient with Parkinson disease and dementia. Neurology 70(3), 238-241.
29. Markopoulou K, Dickson DW, McComb RD, Wszolek ZK, Katechalidou L, Avery L, et al. (2008) Clinical, neuropathological and genotypic variability in SNCA A53T familial Parkinson's disease. Variability in familial Parkinson's disease. Acta Neuropathologica, 116(1), 25-35.
30. Kiely AP, Asi YT, Kara E, Limousin P, Ling H, Lewis P, et al. (2013)-Synucleinopathy associated with G51D SNCA mutation: A link between Parkinson's disease and multiple system atrophy Acta Neuropathologica. epub.
31. Scholz SW, Houlden H, Schulte C, Sharma M, Li A, Berg D, et al. (2009) SNCA variants are associated with increased risk for multiple system atrophy. Annals of Neurology, 65(5), 610-614.
32. Al-Chalabi A, D̈urr A,Wood NW, Parkinson MH, Camuzat A, Hulot J-S, et al. (2009) Genetic variants of the alphasynuclein gene SNCA are associated with multiple system atrophy. PloS One, 4(9), e7114.
33. Kehagia AA, Barker RA, & Robbins TW (2010) Neuropsychological, clinical heterogeneity of cognitive impairment, dementia in patients with Parkinson, disease. Lancet Neurology, 9(12), 1200-1213.
34. Lewis SJG, Foltynie T, Blackwell AD, Robbins TW, Owen AM, & Barker RA (2005) Heterogeneity of Parkinson's disease in the early clinical stages using a data driven approach. Journal of Neurology, Neurosurgery, Psychiatry, 76(3), 343-348.
35. Williams-Gray CH, Evans JR, Goris A, Foltynie T, Ban M, Robbins TW, et al. (2009) The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the Cam-PaIGN cohort. Brain: A Journal of Neurology, 132(Pt 11), 2958-69.
36. Foltynie T, Brayne CEG, Robbins TW, & Barker RA (2004) The cognitive ability of an incident cohort of Parkinson's patients in the U.K. The CamPaIGN study. Brain: A Journal of Neurology, 127(Pt 3), 550-60.
37. Evans AH, Strafella AP, Weintraub D, & Stacy M (2009) Impulsive, compulsive behaviors in Parkinson's disease. Movement Disorders: Official Journal of the Movement Disorder Society, 24(11), 1561-1570.
38. Weintraub D, & Burn DJ (2011) Parkinson's disease: The quintessential neuropsychiatric disorder. Movement Disorders: Official Journal of the Movement Disorder Society, 26(6), 1022-1031.
39. Seppi K, Weintraub D, Coelho M, Perez-Lloret S, Fox SH, Katzenschlager R, et al. (2011) The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease. Movement Disorders: Official Journal of the Movement Disorder Society, 26(Suppl 3), S42-80.
40. Reijnders JSAM, Ehrt U,Weber WEJ, Aarsland D, & Leentjens AFG (2008) A systematic review of prevalence studies of depression in Parkinson's disease. Movement Disorders: Official Journal of the Movement Disorder Society, 23(2), 183-189; quiz 313.
41. Prediger RDS, Matheus FC, Schwarzbold ML, Lima MMS, & Vital MABF (2012) Anxiety in Parkinson's disease: A critical review of experimental and clinical studies. Neuropharmacology, 62(1), 115-124.
42. Frisina PG, Haroutunian V, & Libow LS (2009) The neuropathological basis for depression in Parkinson's disease. Parkinsonism & Related Disorders, 15(2), 144-148.
43. Brooks DJ. Imaging non-dopaminergic function in Parkinson's disease. Molecular Imaging and Biology: MIB: The Official Publication of the Academy of Molecular Imaging, 9(4), 217-22.
44. Richard IH, & Kurlan R (1997) A survey of antidepressant drug use in Parkinson's disease. Parkinson Study Group. Neurology, 49(4), 1168-1170.
45. Richard IH, McDermott MP, Kurlan R, Lyness JM, Como PG, Pearson N, et al. (2012) A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease. Neurology, 78(16), 1229-1236.
46. Skapinakis P, Bakola E, Salanti G, Lewis G, Kyritsis AP, & Mavreas V (2010) Efficacy and acceptability of selective serotonin reuptake inhibitors for the treatment of depression in Parkinson's disease: A systematic review and metaanalysis of randomized controlled trials. BMC Neurology, 10, 49.
47. Dell'Agnello G, Ceravolo R, Nuti A, Bellini G, Piccinni A, D'Avino C, et al. SSRIs do not worsen Parkinson's disease: Evidence from an open-label, prospective study. Clinical Neuropharmacology, 24(4), 221-227.
48. Paumier KL, Siderowf AD, Auinger P, Oakes D, Madhavan L, Espay AJ, et al. (2012) Tricyclic antidepressants delay the need for dopaminergic therapy in early Parkinson's disease. Movement Disorders: Official Journal of the Movement Disorder Society, 27(7), 880-887.
49. Devos D, Dujardin K, Poirot I, Moreau C, Cottencin O, Thomas P, et al. (2008) Comparison of desipramine and citalopram treatments for depression in Parkinson's disease: A double-blind, randomized, placebo-controlled study. Movement Disorders: Official Journal of the Movement Disorder Society, 23(6), 850-857.
50. Kehagia AA, Barker RA, & Robbins TW (2013) Cognitive Impairment in Parkinson's Disease: The Dual Syndrome Hypothesis. Neuro-Degenerative Diseases, 11(2), 79-92.
51. Alves G, Larsen JP, Emre M,Wentzel-Larsen T,&Aarsland D (2006) Changes in motor subtype and risk for incident dementia in Parkinson's disease. Movement Disorders: Official Journal of the Movement Disorder Society, 21(8), 1123-1130.
52. OwenAM,James M, Leigh PN, SummersBA, Marsden CD, Quinn NP, et al. (1992) Fronto-striatal cognitive deficits at different stages of Parkinson's disease. Brain: A Journal of Neurology, 115(Pt 6), 1727-51.
53. Taylor AE, & Saint-Cyr JA (1995) The neuropsychology of Parkinson's disease. Brain and Cognition, 28(3), 281-296.
54. Gotham AM, Brown RG, & Marsden CD (1988) Frontal, cognitive function in patients with Parkinson's disease, "on" and "off" levodopa. Brain: A Journal of Neurology, 111(Pt 2), 299-321.
55. Lange KW, Robbins TW, Marsden CD, James M, Owen AM, & Paul GM (1992) L-dopa withdrawal in Parkinson's disease selectively impairs cognitive performance in tests sensitive to frontal lobe dysfunction. Psychopharmacology, 107(2-3), 394-404.
56. Foltynie T, Goldberg TE, Lewis SGJ, Blackwell AD, Kolachana BS,Weinberger DR, et al. (2004) Planning ability in Parkinson's disease is influenced by theCOMTval158met polymorphism. Movement Disorders: Official Journal of the Movement Disorder Society, 19(8), 885-891.
57. Rakshi JS, Uema T, Ito K, Bailey DL, Morrish PK, Ashburner J, et al. (1999) Frontal, midbrain and striatal dopaminergic function in early and advanced Parkinson's disease A 3D
58. [(18)F]dopa-PET study. Brain: A Journal of Neurology, 122(Pt 9), 1637-1650.
59. Kaasinen V, Nurmi E, Br̈uck A, Eskola O, Bergman J, Solin O, et al. (2001) Increased frontal fluorodopa uptake in early Parkinson's disease: Sex differences in the prefrontal cortex. Brain: A Journal of Neurology, 124(Pt 6), 1125-1130.
60. Arnsten AF (1997) Catecholamine regulation of the prefrontal cortex. Journal of Psychopharmacology (Oxford, England), 11(2), 151-162.
61. Robbins TW (2007) Shifting and stopping: Fronto-striatal substrates, neurochemical modulation and clinical implications. Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences, 362(1481), 917-932.
62. Cools R, Barker RA, Sahakian BJ, & Robbins TW (2001) Enhanced or impaired cognitive function in Parkinson's disease as a function of dopaminergic medication and task demands. Cerebral Cortex (New York, N.Y.: 1991), 11(12), 1136-1143.
63. Emre M, Aarsland D, Albanese A, Byrne EJ, Deuschl G, De Deyn PP, et al. (2004) Rivastigmine for dementia associated with Parkinson's disease. The New England Journal of Medicine, 351(24), 2509-2518.
64. Bohnen NI, Kaufer DI, Ivanco LS, Lopresti B, Koeppe RA, Davis JG, et al. (2003) Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: An in vivo positron emission tomographic study. Archives of Neurology, 60(12), 1745-1748.
65. Burn D, Emre M, McKeith I, De Deyn PP, Aarsland D, Hsu C, et al. (2006) Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease. Movement Disorders: Official Journal of the Movement Disorder Society, 21(11), 1899-1907.
66. Compta Y, Parkkinen L, O'Sullivan SS, Vandrovcova J, Holton JL, Collins C, et al. (2011) Lewy-and Alzheimertype pathologies in Parkinson's disease dementia: Which is more important Brain: A Journal of Neurology, 134(Pt 5), 1493-505.
67. Masliah E, Rockenstein E, Veinbergs I, Sagara Y, Mallory M, Hashimoto M, et al. (2001) beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease. Proceedings of the National Academy of Sciences of the United States of America, 98(21), 12245-12250.
68. Giasson BI, Forman MS, Higuchi M, Golbe LI, Graves CL, Kotzbauer PT, et al. (2003) Initiation and synergistic fibrillization of tau and alpha-synuclein. Science (New York, N.Y.), 300(5619), 636-640.
69. Emmer KL, Waxman EA, Covy JP, & Giasson BI (2011) E46K human alpha-synuclein transgenic mice develop Lewy-like and tau pathology associated with age-dependent, detrimental motor impairment. The Journal of Biological Chemistry, 286(40), 35104-35118.
70. Irwin DJ, White MT, Toledo JB, Xie SX, Robinson JL, Van Deerlin V, et al. (2012) Neuropathologic substrates of Parkinson disease dementia. Annals of Neurology, 72(4), 587-598.
71. De Lau LML, & Breteler MMB (2006) Epidemiology of Parkinson's disease. Lancet Neurology, 5(6), 525-535.
72. LangstonJW, Ballard P,TetrudJW,&Irwin I (1983) Chronic Parkinsonism in humans due to a product of meperidineanalog synthesis. Science (New York, N.Y.), 219(4587), 979-980.
73. Di Monte DA (2003) The environment and Parkinson's disease: Is the nigrostriatal system preferentially targeted by neurotoxins Lancet Neurology, 2(9), 531-538.
74. Hardy J (2010) Genetic analysis of pathways to Parkinson disease. Neuron, 68(2), 201-206.
75. Goedert M, Spillantini MG, Del Tredici K, & Braak H (2013) 100 years of Lewy pathology. Nature reviews. Neurology, 9(1), 13-24.
76. Kr̈uger R, KuhnW,M̈uller T,Woitalla D, Graeber M, K̈osel S, et al. (1998) Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nature Genetics, 18(2), 106-108.
77. Zarranz JJ, Alegre J, Ǵomez-Esteban JC, Lezcano E, Ros R, Ampuero I, et al. (2004) The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Annals of Neurology, 55(2), 164-173.
78. Proukakis C, Dudzik CG, Brier T, Mackay DS, Cooper JM, Millhauser GL, et al. (2013) A novel-synuclein missense mutation in parkinson disease. Neurology, 80(11), 1062-1064.
79. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, & Goedert M (1997) Alpha-synuclein in Lewy bodies. Nature, 388(6645), 839-840.
80. Spillantini MG, Crowther RA, Jakes R, Hasegawa M, & Goedert M (1998) alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. Proceedings of the National Academy of Sciences of the United States of America, 95(11), 6469-6473.
81. Satake W, Nakabayashi Y, Mizuta I, Hirota Y, Ito C, Kubo M, et al. (2009) Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. Nature Genetics, 41(12), 1303-1307.
82. Nalls MA, Plagnol V, Hernandez DG, Sharma M, Sheerin U-M, Saad M, et al. (2011) Imputation of sequence variants for identification of genetic risks for Parkinson's disease: A meta-analysis of genome-wide association studies. LANCET, 377(9766), 641-649.
83. Siḿon-Śanchez J, Schulte C, Bras JM, Sharma M, Gibbs JR, Berg D, et al. (2009) Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nature Genetics, 41(12), 1308-1312.
84. Josephs KA, Parisi JE, & Dickson DW (2002) Alphasynuclein studies are negative in postencephalic parkinsonism of von Economo. Neurology, 59(4), 645-646.
85. Poorkaj P, Bird TD, Wijsman E, Nemens E, Garruto RM, Anderson L, et al. (1998) Tau is a candidate gene for chromosome 17 frontotemporal dementia. Annals of Neurology, 43(6), 815-825.
86. Hutton M, Lendon CL, Rizzu P, Baker M, Froelich S, Houlden H, et al. (1998) Association of missense and 5-splice-site mutations in tau with the inherited dementia FTDP-17. Nature, 393(6686), 702-705.
87. Spillantini MG, Murrell JR, Goedert M, Farlow MR, Klug A, & Ghetti B (1998) Mutation in the tau gene in familial multiple system tauopathy with presenile dementia. Proceedings of the National Academy of Sciences of the United States of America, 95(13), 7737-7741.
88. Ghetti B, Wszolek ZK, Boeve BF, Spina S, & Goedert M (2011) Frontotemporal dementia and parkinsonism linked to chromosome 17. In: Dickson DW, Weller RO, editors. Neurodegeneration: The Molecular Pathology of Dementia and Movement Disorders. Wiley-Blackwell, Oxford, pp. 110-134.
89. Poulopoulos M, Levy OA, & Alcalay RN (2012) The neuropathology of genetic Parkinson's disease. Movement Disorders: Official Journal of the Movement Disorder Society, 27(7), 831-842.
90. Paiśan-Rúz C, Jain S, Evans EW, Gilks WP, Siḿon J, Van der Brug M, et al. (2004) Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron, 44(4), 595-600.
91. Zimprich A, Biskup S, Leitner P, Lichtner P, Farrer M, Lincoln S, et al. (2004) Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron, 44(4), 601-607.
92. Wszolek ZK, Pfeiffer RF, Tsuboi Y, Uitti RJ, McComb RD, Stoessl AJ, et al. (2004) Autosomal dominant parkinsonism associated with variable synuclein and tau pathology. Neurology, 62(9), 1619-1622.
93. Rajput A, Dickson DW, Robinson CA, Ross OA, D̈achsel JC, Lincoln SJ, et al. (2006) Parkinsonism, Lrrk2 G2019S, and tau neuropathology. Neurology, 67(8), 1506-1508.
94. Hardy J, & Revesz T (2012) The spread of neurodegenerative disease. The New England Journal of Medicine, 366(22), 2126-2128.
95. Li J-Y, Englund E, Holton JL, Soulet D, Hagell P, Lees AJ, et al. (2008) Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nature Medicine, 14(5), 501-503.
96. Kordower JH, Chu Y, Hauser RA, Freeman TB, & Olanow CW (2008) Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nature Medicine, 14(5), 504-506.
97. Walker LC, & Levine H (2012) Corruption and spread of pathogenic proteins in neurodegenerative diseases. The Journal of Biological Chemistry, 287(40), 33109-33115.
98. Luk KC, Kehm VM, Zhang B, O'Brien P, Trojanowski JQ, & Lee VMY (2012) Intracerebral inoculation of pathological-synuclein initiates a rapidly progressive neurodegenerative-synucleinopathy in mice. The Journal of Experimental Medicine, 209(5), 975-986.
99. Neudorfer O, Giladi N, Elstein D, Abrahamov A, Turezkite T, Aghai E, et al. (1996) Occurrence of Parkinson's syndrome in type I Gaucher disease. QJM: Monthly Journal of the Association of Physicians, 89(9), 691-694.
100. WestbroekW, Gustafson AM,&Sidransky E (2011) Exploring the link between glucocerebrosidase mutations and parkinsonism. Trends in Molecular Medicine, 17(9), 485-493.
101. Sidransky E, Nalls M a, Aasly JO, Aharon-Peretz J, Annesi G, Barbosa ER, et al. (2009) Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. The New England Journal of Medicine, 361(17), 1651-1661.
102. Gegg ME, BurkeD, Heales SJR, Cooper JM, Hardy J,Wood NW, et al. (2012) Glucocerebrosidase deficiency in substantia nigra of parkinson disease brains. Annals of Neurology, 72(3), 455-463.
103. Brockmann K, Hilker R, Pilatus U, Baudrexel S, Srulijes K, Magerkurth J, et al. (2012) GBA-associated PD: Neurodegeneration, altered membrane metabolism, and lack of energy failure. Neurology, 79(3), 213-220.
104. Neumann J, Bras J, Deas E, O'Sullivan SS, Parkkinen L, Lachmann RH, et al. (2009) Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease. Brain: A Journal of Neurology, 132(Pt 7), 1783-94.
105. Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y, Minoshima S, et al. (1998) Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature, 392(6676), 605-608.
106. Bonifati V, Rizzu P, Van Baren MJ, Schaap O, Breedveld GJ, Krieger E, et al. (2003) Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science (New York, N.Y.), 299(5604), 256-259.
107. Valente EM, Abou-Sleiman PM, Caputo V, Muqit MMK, Harvey K, Gispert S, et al. (2004) Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science (New York, N.Y.), 304(5674), 1158-1160.
108. Kondapalli C, Kazlauskaite A, Zhang N, Woodroof HI, Campbell DG, Gourlay R, et al. (2012) PINK1 is activated by mitochondrial membrane potential depolarization and stimulates Parkin E3 ligase activity by phosphorylating Serine 65. Open Biology, 2(5), 120080.
109. Kilarski LL, Pearson JP, Newsway V, Majounie E, Knipe MDW, Misbahuddin A, et al. (2012) Systematic Review and UK-Based Study of PARK2 (parkin), PINK1, PARK7 (DJ-1) andLRRK2in early-onset Parkinson's disease.Movement Disorders: Official Journal of the Movement Disorder Society, 000(000), 1-8.
110. Youle RJ,&NarendraDP(2011) Mechanisms of mitophagy. Nature Reviews Molecular Cell Biology, 12(1), 9-14.
111. Schapira AH, Cooper JM, Dexter D, Jenner P, Clark JB, & Marsden CD (1989) Mitochondrial complex I deficiency in Parkinson's disease. Lancet, 1(8649), 1269.
112. Saiki M, Baker A, Williams-Gray CH, Foltynie T, Goodman RS, Taylor CJ, et al. (2010) Association of the human leucocyte antigen region with susceptibility to Parkinson's disease. Journal of Neurology, Neurosurgery, and Psychiatry, 81(8), 890-891.
113. Hamza TH, Zabetian CP, Tenesa A, Laederach A, Montimurro J,Yearout D, et al. (2010)Commongenetic variation in the HLA region is associated with late-onset sporadic Parkinson's disease. Nature Genetics, 42(9), 781-785.
114. Pastor P, Ezquerra M, Muñoz E, Mart́i MJ, Blesa R, Tolosa E, et al. (2000) Significant association between the tau gene A0/A0 genotype and Parkinson's disease. Annals of Neurology, 47(2), 242-245.
115. McGeer PL,&McGeer EG (2008) Glial reactions in Parkinson's disease. Movement Disorders: Official Journal of the Movement Disorder Society, 23(4), 474-483.
116. Langston JW, Forno LS, Tetrud J, Reeves AG, Kaplan JA,& Karluk D (1999) Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Annals of Neurology, 46(4), 598-605.
117. McGeer PL, Schwab C, Parent A, & Doudet D (2003) Presence of reactive microglia in monkey substantia nigra years after 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine administration. Annals of Neurology, 54(5), 599-604.
118. Vilariño-G̈uell C, Soto-Ortolaza AI, Rajput A, Mash DC, Papapetropoulos S, Pahwa R, et al. (2011) MAPT H1 haplotype is a risk factor for essential tremor and multiple system atrophy. Neurology, 76(7), 670-672.
119. Goris A, Williams-Gray CH, Clark GR, Foltynie T, Lewis SJG, Brown J, et al. (2007) Tau and alpha-synuclein in susceptibility to, and dementia in, Parkinson's disease. Annals of Neurology, 62(2), 145-153.